肿瘤患者接受酪氨酸激酶抑制剂治疗后乙型肝炎病毒再激活的风险：病例报告及文献分析。
Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis.
机构信息
Department of Biomedical Sciences, Humanitas University, Milan 20072, Italy.
Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Research Hospital, Milan 20089, Italy.
出版信息
World J Gastroenterol. 2024 Mar 7;30(9):1253-1256. doi: 10.3748/wjg.v30.i9.1253.
Abstract
Hepatitis B virus (HBV) reactivation (HBVr) represents a severe and potentially life-threatening condition, and preventive measures are available through blood test screening or prophylactic therapy administration. The assessment of HBVr traditionally considers factors such as HBV profile, including hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen, along with type of medication (chemotherapy; immunomodulants). Nevertheless, consideration of possible patient's underlying tumor and the specific malignancy type (solid or hematologic) plays a crucial role and needs to be assessed for decision-making process.
摘要
乙型肝炎病毒（HBV）再激活（HBVr）是一种严重且可能危及生命的病症，可以通过血液检测筛查或预防性治疗来预防。HBVr 的评估传统上考虑了 HBV 谱等因素，包括乙型肝炎表面抗原（HBsAg）和乙型肝炎核心抗原抗体，以及药物类型（化疗；免疫调节剂）。然而，考虑到患者潜在的肿瘤以及具体的恶性肿瘤类型（实体瘤或血液瘤）也起着至关重要的作用，需要对其进行评估以做出决策。
相似文献
1
Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis.肿瘤患者接受酪氨酸激酶抑制剂治疗后乙型肝炎病毒再激活的风险：病例报告及文献分析。
World J Gastroenterol. 2024 Mar 7;30(9):1253-1256. doi: 10.3748/wjg.v30.i9.1253.
2
Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors.癌症患者接受酪氨酸激酶抑制剂治疗时乙型肝炎病毒再激活的风险。
World J Gastroenterol. 2024 Jun 28;30(24):3052-3058. doi: 10.3748/wjg.v30.i24.3052.
3
Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.乙肝病毒患者异基因造血干细胞移植中的预防性抗病毒治疗。
World J Gastroenterol. 2015 Apr 14;21(14):4284-92. doi: 10.3748/wjg.v21.i14.4284.
4
Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments.血液恶性肿瘤治疗中乙型肝炎病毒再激活导致肝失代偿的风险。
World J Gastroenterol. 2024 Jul 7;30(25):3147-3151. doi: 10.3748/wjg.v30.i25.3147.
5
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.接受抗癌治疗的血液系统恶性肿瘤患者中乙型肝炎病毒再激活的预防与管理
World J Gastroenterol. 2016 Jul 28;22(28):6484-500. doi: 10.3748/wjg.v22.i28.6484.
6
The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients.乙肝生物标志物对HBV/HCV合并感染患者直接抗病毒治疗后HBV再激活的预测作用
Viruses. 2022 Aug 18;14(8):1812. doi: 10.3390/v14081812.
7
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.靶向治疗时代血液系统恶性肿瘤患者乙型肝炎病毒再激活的预防与管理。
World J Gastroenterol. 2023 Sep 7;29(33):4942-4961. doi: 10.3748/wjg.v29.i33.4942.
8
Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors.在布鲁顿酪氨酸激酶抑制剂时代探索乙型肝炎病毒再激活的复杂领域。
World J Gastroenterol. 2024 Jun 7;30(21):2748-2750. doi: 10.3748/wjg.v30.i21.2748.
9
Hepatitis B Reactivation: A Review of Clinical Guidelines.乙型肝炎病毒再激活：临床指南综述。
J Clin Gastroenterol. 2021;55(5):393-399. doi: 10.1097/MCG.0000000000001520.
10
Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand.泰国南部实体器官恶性肿瘤患者接受化疗时乙型肝炎筛查率和再激活情况。
Clin Mol Hepatol. 2019 Dec;25(4):366-373. doi: 10.3350/cmh.2018.0111. Epub 2019 Jul 17.
引用本文的文献
1
Reactivation of hepatitis B virus infection - an important aspect of multifaceted problem.乙型肝炎病毒感染的再激活——多方面问题的一个重要方面。
World J Gastroenterol. 2024 Jul 14;30(26):3193-3197. doi: 10.3748/wjg.v30.i26.3193.
2
Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments.血液恶性肿瘤治疗中乙型肝炎病毒再激活导致肝失代偿的风险。
World J Gastroenterol. 2024 Jul 7;30(25):3147-3151. doi: 10.3748/wjg.v30.i25.3147.
3
Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors.癌症患者接受酪氨酸激酶抑制剂治疗时乙型肝炎病毒再激活的风险。
World J Gastroenterol. 2024 Jun 28;30(24):3052-3058. doi: 10.3748/wjg.v30.i24.3052.
4
Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors.在布鲁顿酪氨酸激酶抑制剂时代探索乙型肝炎病毒再激活的复杂领域。
World J Gastroenterol. 2024 Jun 7;30(21):2748-2750. doi: 10.3748/wjg.v30.i21.2748.
本文引用的文献
1
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.靶向治疗时代血液系统恶性肿瘤患者乙型肝炎病毒再激活的预防与管理。
World J Gastroenterol. 2023 Sep 7;29(33):4942-4961. doi: 10.3748/wjg.v29.i33.4942.
2
Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy.在接受伊布替尼治疗的乙型肝炎病毒表面抗原阴性隐匿性乙型肝炎患者中乙型肝炎病毒再激活。
Virol J. 2023 Aug 1;20(1):168. doi: 10.1186/s12985-023-02140-w.
3
Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors.接受布鲁顿酪氨酸激酶抑制剂治疗的患者中乙型肝炎病毒再激活。
Clin Lymphoma Myeloma Leuk. 2023 Aug;23(8):610-615. doi: 10.1016/j.clml.2023.04.006. Epub 2023 Apr 20.
4
Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment.接受酪氨酸激酶抑制剂治疗的肺癌患者中乙型肝炎病毒的再激活
J Clin Med. 2022 Dec 28;12(1):231. doi: 10.3390/jcm12010231.
5
Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion.乙型肝炎病毒再激活与新型免疫抑制剂和免疫调节剂相关：系统评价、荟萃分析和专家意见。
J Hepatol. 2022 Dec;77(6):1670-1689. doi: 10.1016/j.jhep.2022.07.003. Epub 2022 Jul 16.
6
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.接受依鲁替尼治疗的慢性淋巴细胞白血病患者无论有无抗病毒预防措施时乙肝病毒再激活的风险。一项回顾性多中心GIMEMA研究。
Haematologica. 2022 Jun 1;107(6):1470-1473. doi: 10.3324/haematol.2021.280325.
7
Case of hepatitis B virus reactivation after ibrutinib therapy in which the patient remained negative for hepatitis B surface antigens throughout the clinical course.伊布替尼治疗后发生乙型肝炎病毒再激活的病例，该患者在整个临床过程中乙型肝炎表面抗原始终呈阴性。
Hepatol Res. 2021 Feb;51(2):239-244. doi: 10.1111/hepr.13575. Epub 2020 Oct 8.
8
Risk of hepatitis B virus reactivation in patients treated with ibrutinib.接受依鲁替尼治疗的患者中乙型肝炎病毒再激活的风险。
Blood. 2018 Apr 26;131(17):1987-1989. doi: 10.1182/blood-2018-01-826495. Epub 2018 Feb 28.
Zotero 插件